Patent details

Basic Information

Publication number:

92943

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP037589199

Legal Status:

Active

Application number:

92943

First applicant's nationality:

Procedural language:

French

Paediatric Extension

SPC Extension Filing Date:

10/11/2022

SPC Extension Agent Name:

OFFICE FREYLINGER S.A.

SPC Extension Status:

Granted

SPC Extension Grant Date:

21/10/2024

SPC Extension Rejection Date:

Marketing Authorization

Marketing Authorization Number:

EU/1/15/1032 - Zerbaxa - ceftolozane/tazobactam

Marketing Authorization Type:

Marketing Authorization Date:

22/09/2015

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Dates

Filing date:

12/01/2016

First Marketing Authorization date:

22/09/2015

Grant date:

14/03/2016

Activation date:

27/10/2023

Publication date:

14/03/2016

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

27/10/2028

SPC Extension Expiration:

27/04/2029

Rejection date:

Withdrawal date:

Owner

From:

12/01/2016

 

 

Name:

Astellas Pharma Inc.

Address:

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (JP)

Name:

WAKUNAGA PHARMACEUTICAL CO. LTD.

Address:

5-36, Miyahara 4-chome, Yodogawa-ku, Osaka-shi, Osaka 532-0003, Japan (JP)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

12/01/2016

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Inventor

1

Name:

SATOH Kenji, Wakunaga Pharmaceutical Co., Ltd.

Address:

Japan (JP)

2

Name:

OKUDA Shinya, c/o Astellas Pharma Inc.

Address:

Japan (JP)

3

Name:

MISUMI Keiji, Wakunaga Pharmaceutical Co., Ltd.

Address:

Japan (JP)

4

Name:

YAMANAKA Toshio, c/o Astellas Pharma Inc.

Address:

Japan (JP)

5

Name:

KAWABATA Kohji, c/o Astellas Pharma Inc.

Address:

Japan (JP)

6

Name:

ITOH Kenji, Wakunaga Pharmaceutical Co., Ltd.

Address:

Japan (JP)

7

Name:

OHGAKI Masaru, c/o Astellas Pharma Inc.

Address:

Japan (JP)

8

Name:

OHKI Hidenori, c/o Astellas Pharma Inc.

Address:

Japan (JP)

9

Name:

TODA Ayako, c/o Astellas Pharma Inc.

Address:

Japan (JP)

10

Name:

INOUE Satoshi, Wakunaga Pharmaceutical Co., Ltd.

Address:

Japan (JP)

Publication

Bulletin

1

Bulletin Heading:

SPCX1

Bulletin edition number:

2022/13

Publication date:

01/12/2022

Description:

Section G : Applications for extensions for pediatric use – I1E publication

2

Bulletin Heading:

SPCX2

Bulletin edition number:

2024/13

Publication date:

05/11/2024

Description:

Section H : Granted extensions for pediatric use of supplementary protection certificates – I2E publication

3

Bulletin Heading:

SPC3

Bulletin edition number:

2025/04

Publication date:

04/03/2025

Description:

Section E : Supplementary Protection certificates entered into force – IA publication

Annual Fees

Annual Fee Due Date:

02/11/2026

Annual Fee Number:

24

Annual Fee Amount:

440 Euro

Expected Payer:

Last Annual Fee Payment Date:

14/10/2025

Last Annual Fee Paid Number:

23

Last Annual Fee Paid Amount:

430 Euro

Payer:

OFFICE FREYLINGER S.A.

Filing date	Document type	Number of pages
21/10/2024	Publication	1
21/10/2024	Certificate	1
22/10/2024	Outgoing Correspondence	1
10/11/2022	Application Form	3
10/11/2022	Marketing authorization	3
10/11/2022	General Document	2
10/11/2022	Summary of the product caracteristics	37
10/11/2022	Paediatric investigation plan	127
10/11/2022	Paediatric investigation plan	1
10/11/2022	FNET_DC_FRONTPAGE	1
10/11/2022	Publication	1
10/11/2022	Outgoing Correspondence	1